What are the treatment options for peripheral neuropathy in patients with Waldenström macroglobulinemia?

Updated: May 29, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

A consensus panel from the eighth International Workshop on Waldenström macroglobulinaemia (IWWM8) has proposed treatment recommendations for patients with Waldenström macroglobulinemia.The panel advised that patients with slowly progressing Waldenström macroglobulinemia and/or peripheral neuropathy do not require immediate therapy, but steady progression of neuropathy with accumulating disability should prompt action. Possible options for patients who require treatment are as follows [24] :

  • Rituximab alone
  • Dexamethasone, cyclophosphamide, and rituximab (DRC)
  • Bendamustine-rituximab (BR)
  • Carfilzomib, rituximab, dexamethasone (CARD) or purine analogue combinations
  • Ibrutinib, where available, could be considered in the setting of intolerance of chemotherapy-based therapies or failure of previous therapies

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!